Literature DB >> 7635520

Functional analysis of the effects of a fully humanized anti-CD4 antibody on resting and activated human T cells.

M Bartholomew1, S Brett, K Barber, C Rossman, S Crowe, J Tite.   

Abstract

A fully humanized anti-CD4 antibody was studied for its effects on resting and activated CD4 T cells. Whereas the antibody was poorly lytic, it induced dramatic down-modulation of CD4 expression on both types of cell. In order to down-modulate CD4 on resting, normal CD4 T cells there was an absolute requirement for FcR-mediated cross-linking of the anti-CD4 antibody, and only CD4 levels were affected. When activated cloned T-cell lines were studied there was no requirement for cross-linking and several other cell surface markers were also affected. Although the total cellular CD4 was reduced in the down-modulated cells, as judged by Western blot analysis, that CD4 which remained was associated with p56lck. The results are discussed in relation to the potential use of humanized anti-CD4 antibodies in the therapy of autoimmune disease and the choice of antibody isotype for such a therapeutic antibody.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635520      PMCID: PMC1384022     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

Review 1.  From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease.

Authors:  G Riethmüller; E P Rieber; S Kiefersauer; J Prinz; P van der Lubbe; B Meiser; F Breedveld; J Eisenburg; K Krüger; K Deusch
Journal:  Immunol Rev       Date:  1992-10       Impact factor: 12.988

2.  The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice.

Authors:  P Hutchings; L O'Reilly; N M Parish; H Waldmann; A Cooke
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

3.  Reshaping a therapeutic CD4 antibody.

Authors:  S D Gorman; M R Clark; E G Routledge; S P Cobbold; H Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

4.  "Infectious" transplantation tolerance.

Authors:  S Qin; S P Cobbold; H Pope; J Elliott; D Kioussis; J Davies; H Waldmann
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

5.  Human T cell recognition of influenza A nucleoprotein. Specificity and genetic restriction of immunodominant T helper cell epitopes.

Authors:  S J Brett; J Blau; C M Hughes-Jenkins; J Rhodes; F Y Liew; J P Tite
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

6.  The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis.

Authors:  G S Panayi; J S Lanchbury; G H Kingsley
Journal:  Arthritis Rheum       Date:  1992-07

7.  Humanised monoclonal antibody therapy for rheumatoid arthritis.

Authors:  J D Isaacs; R A Watts; B L Hazleman; G Hale; M T Keogan; S P Cobbold; H Waldmann
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

8.  T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif.

Authors:  K V Prasad; Y C Cai; M Raab; B Duckworth; L Cantley; S E Shoelson; C E Rudd
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 9.  Functional consequences of CD4-TCR/CD3 interactions.

Authors:  M Julius; K Newell; C Maroun; L Haughn
Journal:  Semin Immunol       Date:  1991-05       Impact factor: 11.130

10.  Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG.

Authors:  J Lund; G Winter; P T Jones; J D Pound; T Tanaka; M R Walker; P J Artymiuk; Y Arata; D R Burton; R Jefferis
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

View more
  2 in total

1.  A Proteomic Survey Indicates Sortilin as a Secondary Substrate of the ER Translocation Inhibitor Cyclotriazadisulfonamide (CADA).

Authors:  Victor Van Puyenbroeck; Elisa Claeys; Dominique Schols; Thomas W Bell; Kurt Vermeire
Journal:  Mol Cell Proteomics       Date:  2016-12-20       Impact factor: 5.911

2.  Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds.

Authors:  Liezel A Lumangtad; Elisa Claeys; Sunil Hamal; Amarawan Intasiri; Courtney Basrai; Expedite Yen-Pon; Davison Beenfeldt; Kurt Vermeire; Thomas W Bell
Journal:  Bioorg Med Chem       Date:  2020-10-26       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.